Sigilon Therapeutics (SGTX) Stock Price, News & Analysis

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares.
View SGTX analyst ratings or view top-rated stocks.

2 analysts have issued 12-month target prices for Sigilon Therapeutics' shares. Their SGTX share price targets range from $21.00 to $21.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 6.5%.
View analysts price targets for SGTX or view top-rated stocks among Wall Street analysts.

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($8.19) earnings per share for the quarter, beating analysts' consensus estimates of ($8.58) by $0.39. The company earned $1.95 million during the quarter, compared to analysts' expectations of $3.20 million. Sigilon Therapeutics had a negative net margin of 171.29% and a negative trailing twelve-month return on equity of 83.07%.

Shares of Sigilon Therapeutics reverse split before market open on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Sigilon Therapeutics (SGTX) raised $101 million in an initial public offering on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO.